{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36","upperLimit":"340","value":"86"},{"groupId":"OG001","lowerLimit":"36","upperLimit":"340","value":"86"},{"groupId":"OG002","lowerLimit":"29","upperLimit":"221","value":"125"},{"groupId":"OG003","lowerLimit":"29","upperLimit":"29","value":"29"},{"groupId":"OG004","lowerLimit":"73","upperLimit":"126","value":"99"},{"groupId":"OG005","lowerLimit":"73","upperLimit":"73","value":"73"},{"groupId":"OG006","lowerLimit":"79","upperLimit":"305","value":"192"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"}],"units":"Participants"}],"description":"Interval of time from date of first observed complete or partial response per 2007 International Working Group (IWG) criteria to the date of documented disease progression or death due to any cause, where disease progression is defined by 2007 IWG criteria as any new lesion or increase by ≥ 50% of previously involved sites from nadir. DOR was censored at the time of study withdrawal for hematopoietic stem cell transplant, or at the time of study termination, whichever was earlier, for patients whose disease was still in response.","dispersionType":"Full Range","groups":[{"description":"Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD in the first stage of the study","id":"OG000","title":"Stage 1 (Peripheral T-Cell Lymphoma)"},{"description":"Patients with second-line relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD in the first stage of the study","id":"OG001","title":"Stage 1 (Peripheral T-Cell Lymphoma - Second Line)"},{"description":"Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD in the second stage of the study","id":"OG002","title":"Stage 2 (Peripheral T-Cell Lymphoma)"},{"description":"Patients with second-line relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD in the second stage of the study","id":"OG003","title":"Stage 2 (Peripheral T-Cell Lymphoma - Second Line)"},{"description":"Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD in the expansion stage of the study","id":"OG004","title":"Expansion (Peripheral T-Cell Lymphoma)"},{"description":"Patients with second-line relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD in the expansion stage of the study","id":"OG005","title":"Expansion (Peripheral T-Cell Lymphoma - Second Line)"},{"description":"Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week and valganciclovir 900 mg QD after having been treated with nanatinostat 20 mg QD on Days 1 to 4 per week without response in the monotherapy cohort","id":"OG006","title":"Peripheral T-Cell Lymphoma (Crossover)"}],"paramType":"MEDIAN","populationDescription":"Patients who achieved a CR or PR","reportingStatus":"POSTED","timeFrame":"Up to approximately 2 years","title":"Duration of Response (DOR) by Study Milestone in the Peripheral T-Cell Lymphoma (Combination Therapy) Cohort That Enrolled Patients Beyond Stage 1 or in the Peripheral T-Cell Lymphoma (Monotherapy) Cohort Who Crossed Over to Receive Combination Therapy","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"days"}